BB to boost Covaxin production

The Bharat Biotech on Thursday announced to quickly increase additional manufacturing capacities for COVID-19 vaccine Covaxin by an additional 200 million. The manufacturing capacities for India’s first indigenous COVID vaccine have been ramped up at Chiron Behring Vaccines, a wholly-owned subsidiary of Bharat Biotech at Ankleshwar, Gujarat.

The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety, Hyderabad-based Bharat Biotech said in a statement.